Epstein claims funding anti-polio campaigns in Pakistan and India, old interview goes viral

A previously unseen interview of disgraced financier and convicted sex offender Jeffrey Epstein has surfaced, in which he claims to have donated money to polio eradication campaigns in Pakistan and India.

The interview, recorded at an undisclosed location and time, features Epstein making a number of controversial remarks, including acknowledging his criminal behaviour.

During the exchange, the interviewer questioned Epstein about his moral standing, at one point asking whether he considered himself “evil”.

Epstein responded by saying he did not know how to answer the question, adding that he was not “the devil” and that he feared such a label. When pressed about the source of his wealth, Epstein denied that it was illegitimate, though the interviewer suggested it had been earned by advising individuals involved in serious wrongdoing. Epstein replied that morality was a “complex subject”.

In the interview, Epstein claimed that some of his money had been donated towards polio vaccination efforts in Pakistan and India.

He argued that the focus should be on the outcome of such donations, rather than their source, suggesting that families whose children benefited from vaccination would be less concerned about where the funds originated.

Tweet by Toria Brooke

British media reports have speculated that the interview may have been conducted by Steve Bannon, who served as chief strategist to US president Donald Trump during his first term, though this has not been independently confirmed.

Despite Epstein’s claims, there is no verification that he contributed funds to Pakistan’s polio eradication programme.

It also remains unclear when such donations were allegedly made, through which channels, or under which government they may have taken place.

Jeffrey Epstein, a convicted sex offender accused of sexually abusing underage girls and operating an international trafficking network, died in a US jail in 2019 while awaiting trial.